STAT+: FDA revisits a rare cancer treatment it rejected a few months ago

STAT PlusNewsletterThe Readout FDA revisits a rare cancer treatment it rejected a few months ago Secret drug pricing deals, a virtual AI cancer clinic, and other biotech news from The Readout Manage alerts for this article Email this article Share this article By Meghana KeshavanMay 7, 2026 Biotech Correspondent Meghana Keshavan[email protected]Meghana Keshavan covers biotech and contributes to The Readout newsletter. Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. The Trump administration is touting massive projected savings from its still-secret drug pricing deals, though outside experts say there’s little way to independently verify the math.Advertisement Also, FDA leadership is facing fresh accusations of political interference in drug reviews, AI oncology startups are trying to make cancer care virtual, and scientists are opening up an entirely new frontier of biology hidden inside the “dark proteome.” STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts. Already have an account? Log in Monthly $39 Totals $468 per year $39/month Get Started Totals $468 per year Starter $30 for 3 months, then $399/year $30 for 3 months Get Started Then $399/year Annual $399 Save 15% $399/year Get Started Save 15% 11+ Users Custom Savings start at 25%! Request A Quote Request A Quote Savings start at 25%! 2-10 Users $300 Annually per user $300/year Get Started $300 Annually per user View All Plans To read the rest of this story subscribe to STAT+. Subscribe Log In biotechnology, drug development, Drug prices, research Submit a correction requestReprints Meghana Keshavan Biotech Correspondent Meghana Keshavan covers biotech and contributes to The Readout newsletter. Newsletter Your morning rundown of the science, politics, and money driving biotech today Recommended Biotech May 7, 2026 STAT Plus: FDA to reconsider treatment for rare cancer after its surprise rejection Biotech May 7, 2026 STAT Plus: Next-gen Duchenne drug from Entrada disappoints Advertisement Adam's Biotech Scorecard May 7, 2026 STAT Plus: Color me skeptical: Drinking gold is not an ALS cure Biotech May 7, 2026 STAT Plus: Angelini Pharma buys Catalyst Pharmaceuticals and its rare disease drugs for $4.1B The Readout May 6, 2026 STAT Plus: Novo Nordisk’s less-bad news on its Wegovy pill boosts earnings and share price Subscriber Picks